Skip to content

Scilex Holding Company SCLX Issuance Of Warrants And Exchange Of Liability

Issuance Of Warrants And Exchange Of Liability at other companies

Alto Neuroscience logo
Alto NeuroscienceANRO
$0-100%
NextNav logo
NextNavNN
-$2.25M
Kestra Medical Technologies, Ltd. Common Stock logo
Kestra Medical Technologies, Ltd. Common StockKMTS
$1.36M
BILL Holdings logo
BILL HoldingsBILL
$3.28M+50.0%
NextNav logo
NextNavNN
-$2.25M
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
$409.25K

Other financials

Income statement

See full
Revenue$8.6M+72.1%
Gross profit$4.2M+15.1%
Operating income-$32.2M-15.3%
Net income-$45.7M-75.0%
EPS (diluted)-$6.28-178%

Balance sheet

See full
Cash & equivalents$3.4M-42.2%
Total debt$95.4M+130%
Total equity-$249.2M-17.8%
Total assets$293.6M+272%

Cash flow

See full
Operating cash flow-$1.1M-118%
CapEx$33.3K
Free cash flow$920.8K-63.7%

Valuation

See full
Market cap$54.86M+88.7%
Enterprise value$146.86M+120%
P/S1.6×+1.0×

Profitability

See full
Gross margin59.7%-12.3pp
Operating margin-1,034.4%-1,313pp
Net margin-1,162.4%-1,359pp
FCF margin12.2%

Returns & leverage

See full
Return on equity170.9%
Debt / equity0.3×
Current ratio0.1×0.0×

Where this comes from

Reported directly by Scilex Holding Company in its filing.

Tagged under the XBRL concept sclx:IssuanceOfWarrantsAndExchangeOfLiability.

The official record: Scilex Holding Company’s 10-K, filed April 10, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scilex Holding Company's issuance of warrants and exchange of liability.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scilex Holding Company's issuance of warrants and exchange of liability?
Scilex Holding Company (SCLX) reported issuance of warrants and exchange of liability of $1.56M in Q4 2025.
What does issuance of warrants and exchange of liability mean?
This metric tracks the non-cash financing activity involving the issuance of warrants in exchange for the settlement or modification of existing liability instruments. It reflects the company's strategy for managing its capital structure and debt obligations through equity-linked instruments. Monitoring this helps investors understand potential dilution risks and changes in the company's long-term debt profile.